Catch up on what happened in optometry during the week of January 20-January 24.

The IOLs are equipped with a non-diffractive spiral optic, which allows for a full range of vision with minimized dysphotopsia and 0% loss of transmitted light.

The updated range of lenses feature expanded negative and cylindrical powers, thinner edge thickness, and wider frame options.

Predictive software will use retinal imaging to identify patient risk for Alzheimer disease and other neurodegenerative diseases.

Ocular Services On Demand (OSOD) has operated for over 30 years in ophthalmic preclinical drug development.

The longitudinal study found that visual function and BCVA decreased with an increasing incidence rate of moderate and severe visual impairment for patients with high myopia.

The 3-year, $4.8 million award comes from the NIH Venture Program Oculomics Initiatives.

Preclinical studies evaluating NPI-001 have found that it boosts the endogenous antioxidant glutathione, which stops chemically aggressive oxygen molecules from further damaging retinal cells, according to Nacuity Pharmaceuticals.

Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.

Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.

The Vision Council CEO Ashley Mills detailed what's new and trendy at this year's show during a webinar last week.

Following the switch from multifocal to single-vision contact lenses, axial elongation increased by 0.03 mm/year, and myopia progressed at a rate of −0.17 D annually after switching to single-vision lenses.

The trial met its primary endpoint with statistical significance for the 150mg BID dose, with a proptosis responder rate of 52% (p=0.01).

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

RayTrace has been utilized globally by surgeons since 2008.

Catch up on what happened in optometry during the week of January 13-January 17.

Previously, ClearVision Optical was Revo’s ECP channel distributor for 8 years.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Focused inSights 2024: Frame Buyers found that 78% of providers display between 200 and 1200 frames on their boards, with 70% of providers updating their inventory quarterly.